遗传 ›› 2015, Vol. 37 ›› Issue (1): 41-47.doi: 10.16288/j.yczz.2015.01.006

• 研究报告 • 上一篇    下一篇

成骨不全Ⅰ型家系的基因检测和COL1A2基因新突变的致病性鉴定

李荣1, 郭源平2, 潘敬新3, 郭奕斌1   

  1. 1. 中山大学中山医学院医学遗传学教研室,广州 510080;
    2. 中山大学医学遗传室业余科研小组/广州市第十六中学高二(3)班,广州 510080;
    3. 福建医科大学附属第二医院内科,泉州 362000
  • 收稿日期:2014-07-10 修回日期:2014-09-28 出版日期:2015-01-20 发布日期:2015-01-20
  • 通讯作者: 郭奕斌,副教授,硕士生导师,研究方向:遗传病的分子诊断及产前/植入前基因诊断。E-mail: aguoabin@qq.com E-mail:aguoabin@qq.com
  • 作者简介:李荣,硕士研究生,专业方向:医学遗传学。E-mail: banshou913@126.com
  • 基金资助:
    国家自然科学基金项目(编号:30772069)和闽粤横向科研基金项目(编号:71010025)资助

Genetic screening of a pedigree with osteogenesis imperfecta type Ⅰ and identification of a novel mutation in COL1A2 pathogenic gene

Rong Li1, Yuanping Guo2, Jingxin Pan3, Yibin Guo1   

  1. 1. Department of Medical Genetics, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China; 2. Amateur Team, Department of Medical Genetics, Sun Yat-sen University/ Class 3, Senior 2, The 16th Middle School, Guangzhou 510080, China; 3. Department of Internal Medicine, The Second Affiliated Hospital, Fujian University of Medical Science, Quanzhou 362000, China
  • Received:2014-07-10 Revised:2014-09-28 Online:2015-01-20 Published:2015-01-20

摘要: 为了揭示成骨不全(Osteogenesis imperfecta, OI)Ⅰ型家系的分子遗传学发生机制,文章采用PCR-DNA直接测序法,对患儿COL1A1COL1A2基因共103个外显子(E)进行突变检测。结果显示:患儿COL1A1基因未发现任何病理性突变,而在COL1A2基因E19内发现一新的杂合错义突变(p.G316C),该突变来自其父,而其母正常,其他表型正常的6位亲属也均未发现该突变;通过DHPLC(Denaturing high performance liquid chromatography)筛检,发现患儿与其父均有异常双峰,而其母和所有正常对照均为正常单峰;通过ASA(Allele specific amplification)筛检,患儿与其父均有391 bp的特异扩增带,而其母和所有正常对照均未见特异扩增带;保守性分析结果显示,该突变位点所在甘氨酸在进化上具有高度保守性;SIFT和PolyPhen-2软件预测结果显示,新突变造成的结果是“有害的”和“很可能有害”。上述结果均说明COL1A2基因c.946G>T/p.G316C新突变是导致OI-Ⅰ型的致病性突变,是引起患儿发病的真正内因。患儿父母若再次孕育,可在孕早期进行产前基因诊断或孕前期进行PGD(Preimplantation genetic diagnosis)予以防患。

关键词: 成骨不全Ⅰ, 型, C0L1A2基因, 新突变, 致病性鉴定

Abstract: To uncover the molecular pathogenic mechanism of congenital osteogenesis imperfecta (OI) type I, all the 103 exons of the COL1A1 (Collagen, type Ⅰ, alpha 1) and COL1A2 (Collagen, type Ⅰ, alpha 2) genes in a child with OI type Ⅰ were screened using PCR-DNA direct sequencing. The results showed no pathological mutation in COL1A1 gene, but a novel mutation c.946G>T/p.G316C in the exon 19 of COL1A2 gene, which was inherited from her father. This mutation was not found in her mother and other six phenotypically normal relatives. By denaturing high performance liquid chromatography (DHPLC) screening, the abnormal double-peak was visualized in PCR products of exon 19 of COL1A2 gene in the proband and her father, while the normal single-peak was shown in those of her mother and all the healthy controls. Using allele specific amplification (ASA) screening, a specific band of 391 bp in COL1A2 exon 19 was amplified only in the proband and her father, but not in other samples. The amino acid encoded by the mutation site is evolutionarily highly conserved, and this mutation was a “damaging” or “probably damaging” factor to OI type Ⅰ, based on the predicting results using SIFT and Polyphen-2 softwares. In conclusion, the novel c.946G>T/p.G316C mutation in COL1A2 gene is a pathogenic mutation that could result in OI type Ⅰ. If the couple wants to get pregnant again, it is necessary to screen the mutation site in COL1A2 gene through the prenatal genetic diagnosis in the first trimester or through preimplantation genetic diagnosis (PGD) in the progestation.

Key words: osteogenesis imperfecta type Ⅰ, C0L1A2 gene, novel mutation, pathogenic identification